Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Sponsor's past termination rate: 7.2% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 196 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapycancerhigh riskstatusmetastatic
  Phrases that lowered it: relevantevaluate theto evaluateonce dailyall considerations
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 307 (lowers risk) · Sponsor's track record
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility NCT00714597 · started 2008 · scored riskier than 15% of active trials terminated
• TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer NCT05625932 · started 2023 · scored riskier than 44% of active trials completed
• A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE NCT05171049 · started 2022 · scored riskier than 43% of active trials terminated
• A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE NCT05171075 · started 2022 · scored riskier than 55% of active trials terminated
• A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants NCT02555878 · started 2015 · scored riskier than 33% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.